Loratadine: A Potent, Nonsedating, and Long-Acting H1 Antagonist
Loratadine, a nonclassical selective, peripheral H1-receptor antagonist has undergone extensive preclinical studies and clinical trials in over 6,000 patients. In the treatment of allergic rhinitis, loratadine has efficacy equivalent to clemastine, terfenadine, astemizole, and mequitazine. Its duration of action is 18–24 hours making once daily dosing practical. Loratadine is virtually devoid of sedating or other CNS effects.
No Supplementary Data
No Article Media
Document Type: Research Article
Publication date: 01 July 1987